Lo.G protects medicines in transit
LIVE FROM TOTAL PROCESS & PACKAGING
The Lo.G protects products in transit with the help of a patented 360° impact absorbing buffer system, which ensures that contents are centrally cushioned and protected.
Lo.G packs are made from recycled HDPE plastic. As a nesting product, they offer weight, space and energy savings throughout the supply chain, from warehousing to point-of-sale, when compared with EPS block or foam protective packaging.
Plastique of Tunbridge Wells, Kent offers the Lo.G packaging in single piece ‘wrap-round and lock’ boxes or end cap formats to suit a variety of products.
The company also unveiled Paperlite rPET material developed by Flextrus of Sweden, which is an alternative to thermoformed plastic trays.
According to Plastique’s sales and marketing executive, Daryl Thompson, PaperLite can be used for packaging drugs or medical devices. The material, which looks and feels like paper, is based on FibreForm from Billerud and will run on existing form fill and seal lines. It is also FSC certified and has environmental advantages over thermoformed plastic trays.
PaperLite won the Packaging Innovation Award 2009 at the Scanpack exhibition in Gothenburg.
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
Read moreThe clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Trending Articles
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Logistics
![Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa]()
Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa
Initial implementation begins in Uganda, Kenya and Côte d'Ivoire, connecting screening, diagnosis, referral and long-term management into a unified pathway as the continent accounts for nearly 80% of the global disease burden
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency